Archives
-
Ceftolozane/Tazobactam Against Gram-Negative Resistance
2026-10-01
The reference review examines ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination designed to address resistant Gram-negative infections. Its most important contributions are the integration of mechanism, susceptibility, pharmacokinetic/pharmacodynamic, clinical, and safety evidence for complicated intraabdominal and urinary tract infections.
-
Sulfamonomethoxine: Applied Research Workflows
2026-09-30
Sulfamonomethoxine (SMM) supports controlled DHPS-focused antimicrobial assays, veterinary residue studies, and tiered aquatic toxicity testing. This workflow connects practical stock preparation with species-sensitive ecotoxicology and environmental biotransformation without confusing research benchmarks with treatment recommendations.
-
Temafloxacin Workflows for Antibacterial Research
2026-09-30
Build reproducible MIC, intracellular, respiratory, and comparative antibacterial assays with Temafloxacin. Its DNA-targeting mechanism and broad pathogen coverage support differentiated workflows, provided solvent handling, organism-specific susceptibility, and host-cell controls are rigorously managed.
-
Mitoxantrone HCl Workflows for DNA Damage Research
2026-09-29
Mitoxantrone HCl combines DNA topoisomerase II inhibition with experimentally useful effects on apoptosis, cell-cycle progression, immune signaling, and ERα function. This practical guide covers formulation, dose-response design, mechanistic readouts, resistance-model applications, and troubleshooting for cancer, stem-cell, and neuroimmune studies.
-
PKM2 inhibitor (compound 3k): Assay Workflows
2026-09-29
Build reproducible cancer-metabolism assays around PKM2 inhibitor (compound 3k), from concentration-response testing to ECAR/OCR validation. A complementary macrophage workflow shows how the same PKM2-centered tool can interrogate inflammatory metabolic reprogramming, while highlighting the limits of translating oncology findings into pancreatitis models.
-
SARS-CoV-2 Nucleocapsid Condensation as an Antiviral Target
2026-09-28
Zhao and colleagues showed that RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein supports viral organization and can be disrupted by (-)-gallocatechin gallate. The study connects a condensate mechanism with viral replication, while its variant analysis and cell-based experiments provide a framework for evaluating nucleocapsid-directed antiviral strategies.
-
Tigecycline Workflows for CREC Research
2026-09-28
Use Tigecycline as a complementary phenotypic probe when studying carbapenem-resistant Enterobacter cloacae (CREC), not as a substitute for carbapenemase genotyping or a presumed active treatment. This workflow pairs carefully controlled susceptibility testing with the Guangdong study’s plasmid-transmission framework to separate resistance genotype, phenotype, and strain spread.
-
Gepotidacin in Gonorrhea: From MIC to Cure
2026-09-27
Explore how Gepotidacin’s distinct topoisomerase mechanism connects laboratory susceptibility testing with clinical microbiological outcomes in gonorrhea. This evidence-focused guide interprets the phase 2 findings and turns them into practical considerations for antibacterial research.
-
QRICH1 Links ER Stress to HMGB1 Release in HBV
2026-09-26
The study identifies QRICH1 as an ER-stress-associated effector that amplifies HBV-related HMGB1 transcription, cellular translocation, and secretion, with SIRT6-linked acetylation implicated in HMGB1 trafficking. Results from a chronic rcccDNA mouse model and patient specimens connect this pathway to liver fibrosis, while leaving important questions about causality and therapeutic relevance for future work.
-
β-Blocker Selectivity and Engraftment After HCT
2026-09-25
A 2025 study found that nonselective β-blockade impaired hematopoietic regeneration in mouse transplant models and was associated with delayed platelet engraftment and lower survival after allogeneic HCT, whereas β1-selective inhibition was not. The findings make receptor selectivity, transplant type, posttransplant chemotherapy, and graft cell dose important variables when interpreting adrenergic blockade in transplant research.
-
Gamithromycin: Why Assay Matrix Changes the MIC
2026-09-25
Explore how Gamithromycin susceptibility results can shift when laboratory conditions better reflect a biological matrix. This evidence-focused guide explains a serum-supplemented study, its limits, and how to design more interpretable assays.
-
Partial BACE Inhibition and Synaptic Transmission
2026-09-24
Satir and colleagues tested whether reducing amyloid-beta secretion through partial BACE inhibition could preserve synaptic transmission in cultured rat neurons. Their results suggest that moderate inhibition—associated with less than a 50% reduction in secreted amyloid-beta in this model—did not measurably reduce the functional readout, whereas stronger inhibition coincided with decreased transmission.
-
Gepotidacin vs Nitrofurantoin in EAGLE-2 and EAGLE-3
2026-09-24
The EAGLE-2 and EAGLE-3 phase 3 trials compared oral gepotidacin with nitrofurantoin for uncomplicated urinary tract infection, testing a first-in-class antibiotic with a distinct bacterial topoisomerase mechanism. Gepotidacin was non-inferior in both trials and superior on the primary endpoint in EAGLE-3, while gastrointestinal adverse events—particularly diarrhoea—were more frequent than with nitrofurantoin.
-
LY2603618: A Biomarker-Led Chk1 Strategy
2026-09-23
Explore how LY2603618 can support Chk1 inhibition studies designed around replication stress rather than tumor type alone. A recent HGSOC study identifies low PPP2R2A as a potential sensitivity marker and helps guide more informative assay design.
-
LKB1, Histone Lactylation, and Senescence in LUAD
2026-09-23
The reference study identifies a mechanistic link between LKB1 loss, lactate-associated histone modification, Sp1-dependent TERT transcription, and telomere-driven senescence in lung adenocarcinoma. Its findings support combining telomerase inhibition with metabolic or chemotherapy interventions, while also highlighting the need for careful validation in genetically diverse tumor models.